<DOC>
	<DOCNO>NCT02751099</DOCNO>
	<brief_summary>Bone disorder significant problem chronic kidney disease ( CKD ) , become almost universal stage 5 CKD patient . Besides healthcare cost , bone disorder associate life-threatening complication , include fracture cardiovascular ( CV ) event . Kidney transplantation provide circa 68 % decrease mortality improve co-morbidity . Still , bone disease persist transplantation . The investigator hypothesize bone-derived hormone induce CV event kidney transplant patient . Therefore , early evaluation bone health recommend , prevention complication require . Bone biopsy , invasive expensive method , gold standard bone disorder diagnosis . Therefore , non-invasive predictor bone disease necessary . Classical biochemical marker bone formation resorption show low sensitivity low specificity . New marker , fibroblast growth factor 23 ( FGF23 ) , cofactor klotho , sclerostin promise new marker predict CKD-associated bone CV disease transplantation . This study assess phenotype bone disease transplantation ( give bone histology ) correlation serum FGF23 , klotho sclerostin , order evaluate performance predict CKD-associated bone CV disease .</brief_summary>
	<brief_title>Bone Cardiovascular Disease After Kidney Transplant</brief_title>
	<detailed_description>BACKGROUND . Chronic kidney disease ( CKD ) affect million people worldwide . Cardiovascular ( CV ) event cause 50 % mortality risk CKD patient , relative excess mortality observe young patient , 45 year age . Decreased renal function lead change biochemical parameter ( calcium , phosphorus , PTH vitamin D level ) disturb mineral metabolism , translate different bone disorder ( relate bone turnover , mineralization , volume ) associate extra-skeletal calcification . Bone disease stage CKD associate CV morbidity . This cross-talk bone vessel constitute systemic syndrome know CKD-mineral bone disorder ( CKD-MBD ) , think one major non-traditional risk factor extremely high rate mortality observe disease . CKD-MBD classify four major histological group ( term turnover , mineralization volume ) : hyperparathyroid bone disease ( high turnover disease , normal mineralization variable volume ) ; adynamic bone disease ( low turnover disease , normal mineralization decrease bone volume ) ; osteomalacia ( low turnover disease , reduce mineralization normal high bone volume ) ; mixed renal osteodystrophy ( reduce mineralization without increase bone formation ) . Kidney transplantation treatment choice establish stage 5 CKD . Even correction uremia , post-transplant MBD frequent reflect pre-existing CKD-MBD , effect renal dysfunction transplantation , effect consequence immunosuppression . Transplanted patient CKD-MBD reduce quality life require medical assistance bone pain , fracture CV event . Indeed , cardiovascular disease remain leading cause death renal transplantation , still double risk general population . The gold standard diagnosis CKD-associated bone disease bone biopsy , expensive invasive procedure . Non-invasive marker bone disease presently lack sufficient specificity sensitivity allow differential diagnosis renal osteodystrophy . New biomarkers need , osteocyte-derived factor , FGF23 sclerostin , promise answer . FGF23 act phosphaturic hormone , suppressor vitamin D non-consensual effect parathyroid hormone ( PTH ) . FGF23 specific receptor need co-factor , klotho protein , perform majority function . Serum klotho level CKD low , influence resistance FGF23 activity . What happen transplanted patient yet totally understood ; study point endothelial dysfunction cardiovascular disease mediate factor transplant setting . Besides , graft loss mortality relate high serum level FGF23 bone mineral density loss relation histological bone disease unknown . Sclerostin glycoprotein product SOST gene osteocytes act negative regulator bone metabolism . Various observation show CKD patient high sclerostin serum level , thus potential role renal osteodystrophy . The correlation serum level sclerostin histomorphometric parameter bone turnover , osteoblast number function renal transplant patient yet know . The impact high sclerostin level CV disease mortality yet determine . Studies relate sclerostin level CV mortality dialysis patient inconsistent . Studies renal transplant patient lack . AIMS . The investigator study relationship new osteocyte-derived biomarkers bone disease , FGF23 ( klotho ) sclerostin , bone histologic change CV event baseline one year transplantation . If association find , performance biomarkers predictor CKD-MBD determine . METHODS . Prospective cohort study convenience , consecutive sample de novo renal transplanted patient . At recruitment , data collect aetiology CKD , presence diabetes , hypertension , hyperparathyroidism , hepatitis virus , ovulation status woman ( menopause ) , active pre-transplant medication ( emphasis vitamin D analogue , calcimimetics , phosphate binder ) , echocardiography ( M mode 2D ) , Teresa Adrag√£o score vascular calcification ( hand pelvis x-ray ) , HLA phenotype mismatch , donor data ( age , gender , cause death ) , cold ischemia time . Patients followed-up 1 year , data record immunosuppressive regimen ( cumulative dos ) , CV event ( myocardial infarction , congestive heart failure , arrhythmia ) , fracture , rejection episode , graft loss ( cause ) , death ( CV [ fatal myocardial infarction , sudden death fatal congestive heart failure ] , infection , malignancy ) . At end follow-up , echocardiogram ( M mode 2D ) score vascular calcification perform . Serum creatinine , urea , ionogram , uric acid , calcium , phosphorus , magnesium , bone alcaline phosphatase assess use standard method . PTH measure immuno-chemiluminescence use second-generation assay ( Immulite 2000 ; Siemens Medical Solutions Diagnostics , Los Angels , CA ) . Vitamin D [ 25 ( OH ) D 1,25 ( OH ) 2D ] measure radioimmunoassay provide IDS ( Boldon , UK ) . Two bone biopsy propose patient ( renal transplantation procedure , already general anaesthesia , circa 12 month transplantation , local anaesthesia ) . Bone biopsy make use 7G trocar ( Osteobell T ) , manual puncture . After process bone fragment ( fixation , dehydration methylmethacrylate impregnation ) , routine staining use : von Kossa , Goldner trichrome , acid phosphatase ( selective staining osteoclast ) , Perls . Cortical bone evaluate separately trabecular bone . Cortical bone volume cortical thickness measure . Bone biopsies describe : bone remodelling degree cellular activation ( specific score ) ; efficacy mineralization ; quantification possible metal deposit . In order evaluate rate bone formation rate mineral deposition , patient prescribe tetracycline hydrochloride , 500mg , 12/12 hour three day , one month one week 2nd bone biopsy , case live donor transplantation , 1st 2nd bone biopsy . At time point bone biopsy [ day 0 ( pre-transplant ) nearly month 12 ] serum level FGF23 , cofactor Klotho , sclerostin measure immunology lab hospital , accord manufacturer 's instruction . C-terminal FGF23 measure sandwich ELISA ( Immunotopics , San Clement , CA ) . Alfa-klotho measured ELISA ( IBL America , MN , USA ) . Sclerostin assess TECO Sclerostin EIA kit , 96-well immune-capture ELISA ( Sissach , Switzerland ) . Comparisons bone biopsy transplantation assess pair t-test ( compare score ) pair McNemar 's test ( switch score categorical variable ) . Multivariable analysis adjust age , gender , diabetes , immunosuppressive regiment and/or cumulative dos , renal function perform identify independent risk factor disease type severity . In female , menopause consider effect modifier bone volume . Comparisons FGF23 , Klotho sclerostin pre post-transplant make paired t-test , assume normal distribution . Associations FGF23 , Klotho sclerostin level demographic data biochemical parameter two time-points also access t-test , Pearson test linear regression , whenever applicable . A multivariable analysis execute control confounders ( age , gender , diabetes , PTH , renal function , immunosuppressive regiment ) . Associations FGF23 , Klotho sclerostin bone turnover , mineralization volume explore regression model . The potential effect FGF23 sclerostin CV health explore use regression model .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Patients eligible kidney transplantation . mental retardation , liverkidney transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>